EQ Company Profile and Key Details

Q: Who are the executives of EQ?

Ms. Maple Fung M.D.Chief Medical OfficerDr. Stephen Connelly Ph.D.Chief Scientific Officer & DirectorMr. Jason A. KeyesChief Financial OfficerDr. Krishna R. Polu M.D.ConsultantMr. Daniel Mark BradburyExecutive ChairmanMatthew Ritter Ph.D.Senior Vice President of Corporation Devel.Mr. Bruce D. Steel C.F.A.Co-Founder, Pres, Chief Executive Officer & DirectorMs. Christine Zedelmayer M.B.A., P.M.P.Senior Vice President & Chief Operating OfficerMr. Joel M. RothmanChief Devel. Officer

NASDAQ : EQ

Equillium

$2.86

-0.19-6.23%

At Close 4:00 PM

62.42

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Equillium, Inc. (EQ) stock declined over -6.23%, trading at $2.86 on NASDAQ, down from the previous close of $3.05. The stock opened at $3.06, fluctuating between $2.82 and $3.15 in the recent session.

Stock Snapshot

3.05

Prev. Close

101.59M

Market Cap

2.82

Day Low

-13.62

P/E Ratio

-0.21

EPS (TTM)

-0.62

Cash Flow per Share

3.06

Open

35.52M

Number of Shares

3.1492

Day High

49.39%

Free Float in %

0.64

Book Value

273.92K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 22, 2026	3.04	3.15	2.82	2.86	274.55K
Jun 18, 2026	3.02	3.12	2.98	3.05	424.52K
Jun 17, 2026	2.77	3.09	2.70	2.99	699.06K
Jun 16, 2026	2.82	2.89	2.68	2.75	254.94K
Jun 15, 2026	2.84	2.92	2.78	2.80	362.13K
Jun 12, 2026	2.80	2.96	2.71	2.81	441.28K
Jun 11, 2026	2.74	2.98	2.62	2.81	554.67K
Jun 10, 2026	2.70	2.90	2.66	2.67	387.99K
Jun 09, 2026	2.80	2.97	2.62	2.70	433.44K
Jun 08, 2026	2.88	2.95	2.65	2.77	662.52K
Jun 05, 2026	3.12	3.14	2.76	2.94	1.14M
Jun 04, 2026	3.11	3.39	3.05	3.17	1.85M
Jun 03, 2026	2.79	3.45	2.71	3.11	3.69M
Jun 01, 2026	2.90	3.12	2.80	3.08	4.46M
May 29, 2026	2.96	3.00	2.76	2.90	853.87K
May 28, 2026	2.70	3.10	2.69	2.84	1.9M
May 27, 2026	2.32	2.74	2.26	2.63	763.7K
May 26, 2026	2.31	2.35	2.21	2.32	269.64K
May 22, 2026	2.23	2.39	2.20	2.26	467.39K
May 21, 2026	2.03	2.23	1.99	2.21	274.76K

Contact Details

La Jolla, CA 92037

United States

https://equilliumbio.com 858 412 5302

About Company

Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.

Stock Peers

ARGX

26.03+2.97%

argenx SE$903.75 REGN

2.56+0.42%

Regeneron Pharmaceuticals, Inc.$612.50 UTHR

1.70998+0.32%

United Therapeutics Corporation$538.30 MDGL

7.13+1.41%

Madrigal Pharmaceuticals, Inc.$512.88 VRTX

15.16+3.36%

Vertex Pharmaceuticals Incorporated$466.79 KRYS

-4.63-1.33%

Krystal Biotech, Inc.$343.43 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

21.08+7.47%

Praxis Precision Medicines, Inc.$303.39 ALNY

8.32+2.99%

Alnylam Pharmaceuticals, Inc.$286.41 LGND

-12.71-4.62%

Ligand Pharmaceuticals Incorporated$262.17

Company Overview

Equillium, Inc. (NASDAQ:EQ) closed at $2.86 USD, losing -$0.19 (-6.23%) from the previous close of $3.05. The stock is currently mid-range between its 52-week high and low $0.27 and $3.45. With a market capitalization of about $101.59 million, Equillium, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.78). Key stats such as the average daily volume over the past year has been around 607.93 thousand shares, volume is running light vs its 52-week average. Headquartered in La Jolla, CA, Equillium, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Bruce D. Steel, the company employs approximately 35 people and listed since October 12, 2018. Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient.

Technical Performance

EQ has shown mixed momentum, losing 0.0% over the past week and -21.23% over the past quarter, though year-to-date performance is down -25.81%. Short-term trend indicators are bearishly aligned (SMA20 7.58%, SMA50 22.78%, SMA200 63.35%). The stock’s 14-day RSI is 59.56 (neutral), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -26.17% below its high and over 542.59% above its low. Average 10-day trading volume of 403.04 thousand shares is below the 3-month average of 567.35 thousand, indicating normal recent market interest.

Valuation Metrics

Equillium, Inc. trades at a P/E ratio of -8.12, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.94 trading at moderately above to book value. The P/FCF stands at -5.73, also above market averages.

Dividend & Fair Value

Equillium, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.32. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Equillium, Inc. generated EPS of -$0.63 over the past year. Five-year average earnings growth is 31.13%. Wall Street analysts project EPS growth of -1.9% annually over the next five years. The latest quarter delivered EPS of -$0.06. The next quarter is forecast at -$0.06. Next year's EPS is expected at $42.00. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $6.00. The high target offers 319.58% upside. The low target suggests 109.79% downside. The mean target is $9.43. This offers 229.72% upside. Equillium, Inc. earnings surprise history is a mixed track record. The quarter that ended May 13, 2026, missed forecasts by 50.0%. The prior quarter beat by -42.86%. Over the last six quarters, Apple has recorded several small beats. These include -27.27% in March 27, 2025.

Shareholding & Insider Activity

Equillium, Inc. has 35.72 million shares outstanding. The public float is 42.08 million shares, elevated short interest at 1.90% of float. This equals 427.86 thousand shares. The short ratio is 0.82 days. Institutional investors hold 14.96% of the float. Insiders own 21.55%. Connelly Stephen holds 762.02 thousand shares, Zedelmayer Christine has 62.59 thousand shares and Keyes Jason A has 37.72 thousand shares. Over the past six months, insider transactions show net selling. They sold 805.21 thousand shares across 11 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Equillium generated $36.08M in revenue, or $1.04 per share. Gross margin was 99.65%, operating margin -40.24%, and net profit margin -36.96%. Returns are negative, with ROA at -26.39% and ROE at -59.08%.
On valuation metrics, Equillium trades at a P/E of -8.12, P/S of 0.00 and P/B of 4.94. The current ratio is 18.62 and quick ratio is 18.62. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -5983.23 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -27.28.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Equillium posted revenue of $36.08M, down slightly from $15.76M in the prior quarter. Gross profit was $35.96M (margin 99.65%). Operating income was - $14.52M (margin -40.2%). Net income was- $13.34M (EPS - $0.38).
The company ended the quarter with $40.87M in cash and short-term investments, a total debt of $824.00K, and net debt of - $22.39M. Total assets were $50.53M, with equity of $22.57M. Financials further reflected weakness, with operating cash flow of - $21.78M, free cash flow of - $21.83M, and capital expenditures of - $50.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Equillium, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 10.49%, with price expected at $3.16 by July 06, 2026, within a range of $2.88 to $3.45 3-Month Outlook: Projected rise of 336.36%, reaching $12.48 by September 18, 2026, with a range of $12.43 to $12.56. 1-Year Outlook: Projected gain of 771.68%, with price at $24.93 by June 22, 2027, within a range of $22.78 to $33.96.

Key Takeaways

Equillium, Inc. (NASDAQ:EQ) shares are down -25.81% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Equillium, Inc. trading at a premium to the broader market with a P/E of -8.12. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.90, suggesting 246.15% upside. Our AI forecast model points to short-term strength (10.49% over two weeks), a medium-term rise (336.36% over three months), and a longer-term gain (771.68% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Equillium, Inc. (EQ) stock price?

Equillium, Inc. (NASDAQ: EQ) stock price is $2.86 in the last trading session. During the trading session, EQ stock reached the peak price of $3.15 while $2.82 was the lowest point it dropped to. The percentage change in EQ stock occurred in the recent session was -6.23% while the dollar amount for the price change in EQ stock was - $0.19.

EQ's industry and sector of operation?

The NASDAQ listed EQ is part of Biotechnology industry that operates in the broader Healthcare sector. Equillium, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of EQ?

Ms. Maple Fung M.D.
Chief Medical Officer
Dr. Stephen Connelly Ph.D.
Chief Scientific Officer & Director
Mr. Jason A. Keyes
Chief Financial Officer
Dr. Krishna R. Polu M.D.
Consultant
Mr. Daniel Mark Bradbury
Executive Chairman
Matthew Ritter Ph.D.
Senior Vice President of Corporation Devel.
Mr. Bruce D. Steel C.F.A.
Co-Founder, Pres, Chief Executive Officer & Director
Ms. Christine Zedelmayer M.B.A., P.M.P.
Senior Vice President & Chief Operating Officer
Mr. Joel M. Rothman
Chief Devel. Officer

How EQ did perform over past 52-week?

EQ's closing price is 959.26% higher than its 52-week low of $0.27 where as its distance from 52-week high of $3.45 is -17.1%.

How many employees does EQ have?

Number of EQ employees currently stands at 35.

Link for EQ official website?

Official Website of EQ is: https://equilliumbio.com

How do I contact EQ?

EQ could be contacted at phone 858 412 5302 and can also be accessed through its website. EQ operates from 2223 Avenida De La Playa, La Jolla, CA 92037, United States.

How many shares of EQ are traded daily?

EQ stock volume for the day was 273.92K shares. The average number of EQ shares traded daily for last 3 months was 607.94K.

What is the market cap of EQ currently?

The market value of EQ currently stands at $101.59M with its latest stock price at $2.86 and 35.52M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	35
Beta	1.76
Sales or Revenue	$36.08M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

EQ Company Profile and Key Details

Equillium

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Earnings & Analyst Outlook

Valuation Metrics

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook